Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 2.95 below Zevra Therapeutics Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 237 other companies have achieved higher Quick Ratio than Zevra Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 713 to 1121.

Explain Quick Ratio?
How much Cash & cash equivalents ZVRA�s has?
What are ZVRA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ZVRA/financial-strength

https://api.csimarket.com/api/v1/companies/ZVRA/fundamentals

https://api.csimarket.com/api/v1/companies/ZVRA/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ZVRA Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	58.43 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-38.78 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	2.95	Subscribe	Subscribe	Subscribe	Subscribe
ZVRA's Total Ranking	# 1121	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-14.93 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-15.95 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 238
Healthcare Sector	# 407
Overall Market	# 1121

Quick Ratio Statistics
High	Average	Low
39.27	7.62	0.03
(Sep 30 2021)		(Mar 31 2020)

Financial Statements
Zevra Therapeutics Inc 's Current Liabilities	$ 41 Millions	Visit ZVRA's Balance sheet
Zevra Therapeutics Inc 's Cash & cash equivalent	$ 122 Millions	Visit ZVRA's Balance sheet
Source of ZVRA's Sales		Visit ZVRA's Sales by Geography

Cumulative Zevra Therapeutics Inc 's Quick Ratio

ZVRA's Quick Ratio for the trailling 12 Months

ZVRA Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	52.01 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	23.37 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	3.74	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 802	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	9.47 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-10.5 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ZVRA Financial Strength Comparisons >> Go to Compare ZVRA Quick Ratio to its Competitors

On the trailing twelve months basis Due to fall in Current Liabilities in the Q3 2026 to $41.37 millions, cumulative Quick Ratio decreased to 3.74 below the Zevra Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 431 other companies have achieved higher Quick Ratio than Zevra Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3511 to 3797.

Explain Quick Ratio?
How much Cash & cash equivalents ZVRA�s has?
What are ZVRA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 432
Healthcare Sector	# 879
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
28.3	4.71	0.08
(Mar 31 2022)		(Sep 30 2020)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Arvinas Inc	7.98	$ 558.400 Millions	$ 70.000 Millions
Pliant Therapeutics Inc	7.90	$ 141.614 Millions	$ 17.921 Millions
Wave Life Sciences Ltd	7.87	$ 431.012 Millions	$ 54.760 Millions
Savara Inc	7.80	$ 129.649 Millions	$ 16.630 Millions
Rigel Pharmaceuticals Inc	7.79	$ 224.456 Millions	$ 28.806 Millions
Cytomx Therapeutics Inc	7.64	$ 347.980 Millions	$ 45.532 Millions
Atea Pharmaceuticals Inc	7.64	$ 191.199 Millions	$ 25.025 Millions
Braveheart Bio, Inc.	7.27	$ 121.291 Millions	$ 16.673 Millions
Viking Therapeutics Inc	7.17	$ 959.813 Millions	$ 133.897 Millions
Scynexis Inc	7.09	$ 47.165 Millions	$ 6.652 Millions
Lb Pharmaceuticals Inc	7.03	$ 215.075 Millions	$ 30.573 Millions
Zentalis Pharmaceuticals Inc	7.03	$ 228.893 Millions	$ 32.539 Millions
Quoin Pharmaceuticals Ltd	6.95	$ 33.184 Millions	$ 4.776 Millions
Vera Therapeutics Inc	6.89	$ 384.042 Millions	$ 55.775 Millions
Nuvation Bio Inc	6.73	$ 663.370 Millions	$ 98.559 Millions
Ensysce Biosciences Inc	6.71	$ 29.671 Millions	$ 4.419 Millions
Anaptysbio Inc	6.71	$ 230.319 Millions	$ 34.318 Millions
Coya Therapeutics Inc	6.64	$ 35.802 Millions	$ 5.395 Millions
Capricor Therapeutics inc	6.61	$ 197.581 Millions	$ 29.895 Millions
Arcturus Therapeutics Holdings Inc	6.52	$ 184.817 Millions	$ 28.345 Millions
Moonlake Immunotherapeutics	6.50	$ 379.704 Millions	$ 58.430 Millions
Kiora Pharmaceuticals Inc	6.47	$ 16.287 Millions	$ 2.519 Millions
Camp4 Therapeutics Corporation	6.27	$ 124.522 Millions	$ 19.865 Millions
Context Therapeutics Inc	6.26	$ 34.411 Millions	$ 5.501 Millions
Sagimet Biosciences inc	6.22	$ 236.397 Millions	$ 37.985 Millions
Bridgebio Oncology Therapeutics Inc	6.18	$ 315.331 Millions	$ 51.026 Millions
Cartesian Therapeutics Inc	6.12	$ 122.975 Millions	$ 20.088 Millions
Olema Pharmaceuticals Inc	5.98	$ 413.771 Millions	$ 69.233 Millions
Summit Therapeutics Inc	5.71	$ 629.899 Millions	$ 110.226 Millions
Nurix Therapeutics Inc	5.51	$ 720.458 Millions	$ 130.742 Millions

Date modified: 2026-11-06T12:58:20+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.